LRRK2-IN-14 (30 mg/kg; p.o.; single dose) inhibits phosphorylation of G2019S mutant LRRK2 in the brain in ICR mice[1].
Pharmacokinetic Analysis in ICR mice[1]
| Route | Dose (mg/kg) | C0 (ng/mL) | Cmax (ng/mL) | Tmax (h) | t1/2 (h) | Vdss (mL/kg) | Clobs (mL/min/kg) | AUC0-last (ng·h/mL) | AUC0-INF (ng·h/mL) | MRT0-INF (h) | F (%) |
| i.v. | 5 | 4101 | / | / | 0.905 | 1233 | 16.3 | 5122 | 5181 | 1.27 | / |
| p.o. | 5 | / | 2803 | 0.083 | 0.709 | / | / | 3657 | 3672 | 1.22 | 70.9 |
| brain | 5 | / | 837 | 0.292 | 0.648 | / | / | 1230 | 1233 | 1.14 | / |
| Animal Model: | ICR mice[1] |
| Dosage: | 30 mg/kg |
| Administration: | p.o.; single dose |
| Result: | Reduced phosphorylated LRRK2 levels to 34%. |